Swedish firm builds thykaloid weight loss data for EFSA ahead of 2013 launch
A human, clinical trial has begun with spinach-derived thyrakoids and appetite endpoints, designed and run in conjunction with German consultancy, analyze&realize.
It is expected to complete by year’s end.
“Beside the EFSA [European Food Safety Authority] weight-loss study, others at Lund University and in the US are scheduled for this year,” the company said.
“Green Leaf Medical AB plans to introduce its appetite-reducing thylakoids, which can have applications in supplements and functional foods and drinks, in late 2012 or early 2013.Formulation methods for thylakoids in solid and liquid form have been developed.”
Research has shown that thylakoids can reduce appetite, and prevent the assimilation of fat and carbohydrates.
In plants, thylakoids form membranes that are responsible for photosynthesis.
With regard to submitting a dossier to the European Union nutrition and health claims regulation (NHCR), spokesperson Miłosz Poprawski noted, “we are strictly following EFSA guidelines in our final studies before filing for EFSA claims late this year.”
Research conducted by Lund University in Sweden has found that, “thylakoid membranes effectively stabilise oil-in-water emulsions, which should facilitate their incorporation in food with satiety-promoting effect.”
Poprawski said the company was targeting mid-level-marketers, supermarkets, health food stores, pharmacies as well as health care professionals.
Food supplements, meal replacements, appetite shots and functional food and drinks are the target markets.
